Novel Roflumilast analogs as soft PDE4 inhibitors

被引：32

作者：

Boland, Sandro ^{[1
]}

Alen, Jo ^{[1
]}

Bourin, Arnaud ^{[1
]}

Castermans, Karolien ^{[1
]}

Boumans, Nicki ^{[1
]}

Panitti, Laura ^{[1
]}

Vanormelingen, Jessica ^{[1
]}

Leysen, Dirk ^{[1
]}

Defert, Olivier ^{[1
]}

机构：

[1] Amakem NV, B-3590 Diepenbeek, Belgium

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 18期

关键词：

PDE4; inhibitors; Soft drug; SAR; Esterase; COPD; PHOSPHODIESTERASE-4; INHIBITORS; ASTHMA;

D O I：

10.1016/j.bmcl.2014.07.016

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

PDE4 inhibitors are of high interest for treatment of a wide range of inflammatory or autoimmune diseases. Their potential however has not yet been realized due to target-associated side effects, resulting in a low therapeutic window. We herein report the design, synthesis and evaluation of novel PDE4 inhibitors containing a gamma-lactone structure. Such molecules are designed to undergo metabolic inactivation when entering circulation, thereby limiting systemic exposure and reducing the risk for side effects. The resulting inhibitors were highly active on both PDE4B1 and PDE4D2 and underwent rapid degradation in human plasma by paraoxonase 1. In contrast, their metabolites displayed markedly reduced permeability and/or on-target activity. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：4594 / 4597

页数：4

共 50 条

[1] NOVEL PDE4 INHIBITORS DEMONSTRATE SUPERIOR EFFICACY AND SAFETY COMPARED TO ROFLUMILAST
Sanders, V. J.
Akama, T.
Chen, C. -W
Bu, W.
Liu, L.
Dong, C.
Jarnagin, K.
INFLAMMATION RESEARCH, 2010, 59 : S295 - S295
[2] Novel PDE4 inhibitors
Lloyd, A
DRUG DISCOVERY TODAY, 2000, 5 (04) : 166 - 166
[3] An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma
Al-Sajee, Dhuha
Yin, Xuanzhi
Gauvreau, Gail M.
EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (05) : 609 - 620
[4] Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors
Wollin, L.
Bundschuh, D. S.
Wohlsen, A.
Marx, D.
Beume, R.
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2006, 19 (05) : 343 - 352
[5] Rhodanine derivatives as novel inhibitors of PDE4
Irvine, Mark W.
Patrick, Graham L.
Kewney, Justin
Hastings, Stuart F.
MacKenzie, Simon J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (06) : 2032 - 2037
[6] PDE4 inhibitors
Lloyd, AW
DRUG DISCOVERY TODAY, 2000, 5 (12) : 571 - 571
[7] The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice
Vollert, S.
Kaessner, N.
Heuser, A.
Hanauer, G.
Dieckmann, A.
Knaack, D.
Kley, H. P.
Beume, R.
Weiss-Haljiti, C.
DIABETOLOGIA, 2012, 55 (10) : 2779 - 2788
[8] The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice
S. Vollert
N. Kaessner
A. Heuser
G. Hanauer
A. Dieckmann
D. Knaack
H. P. Kley
R. Beume
C. Weiss-Haljiti
Diabetologia, 2012, 55 : 2779 - 2788
[9] PDE4 inhibitors 1998
Norman, P
EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (07) : 771 - 784
[10] PDE4 inhibitors 1999
Norman, P
EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (08) : 1101 - 1118

← 1 2 3 4 5 →